Retatrutide for Women: What the Clinical Data Shows

Retatrutide's Phase 2 obesity trial (Jastreboff et al., NEJM 2023) enrolled 338 adults, approximately 48% of whom were women. The trial achieved up to 24.2% mean weight loss at 48 weeks with the 12mg dose — the highest weight loss ever reported for an obesity drug at that time.

But the published data does not break out results by sex in detail. The Phase 2 paper included prespecified exploratory subgroup analyses (Figure 2), but the topline TRIUMPH Phase 3 results announced so far have not published sex-stratified outcomes. This means we do not yet have retatrutide-specific data on whether women respond differently than men.

What we do have is a substantial body of evidence from GLP-1 and dual-agonist drugs showing that sex matters — for side effects, fertility, body composition, and drug interactions. This page covers what women should know based on the available evidence.

Retatrutide is an investigational drug that has not been approved by the FDA.

Women-Specific Concerns at a Glance

Side Effects: Women Report More GI Symptoms

Across the GLP-1 drug class, women consistently experience higher rates of gastrointestinal side effects than men. A large real-world analysis found that women experience nausea and vomiting at approximately 2.5 times the rate of men. Higher estrogen levels correlate with more severe GI side effects, suggesting a hormone-drug interaction rather than a purely dose-related effect.

In retatrutide's Phase 2 obesity trial, nausea was the most common adverse event across all dose groups (reported in up to 45% of participants in the highest-dose escalation group). However, the published data does not break this down by sex.

What this means for women considering retatrutide

• Slower dose titration may reduce GI side effects — this is standard clinical practice and is built into retatrutide's dosing schedule
• Women who have experienced significant nausea on semaglutide or tirzepatide should discuss this history with their physician
• Despite higher side effect rates, women typically achieve greater weight loss than men on GLP-1 drugs

Oral Contraceptives: A Potential Drug Interaction

GLP-1 drugs slow gastric emptying, which can delay absorption of oral medications — including birth control pills. The clinical significance varies by drug:

• Semaglutide does not significantly reduce oral contraceptive bioavailability. A dedicated pharmacokinetic study confirmed no meaningful interaction with ethinylestradiol/levonorgestrel.
• Tirzepatide reduces absorption of oral contraceptives by approximately 20% (AUC). The FDA label for Mounjaro/Zepbound advises using a backup or non-oral contraceptive method for 4 weeks after initiation and after each dose escalation.

Retatrutide, like tirzepatide, contains GIP receptor agonist activity — and both GIP and GLP-1 agonism slow gastric emptying. No dedicated drug interaction study for retatrutide and oral contraceptives has been published. Until such data is available, the tirzepatide precedent suggests caution.

Practical recommendations

• Consider non-oral contraceptive methods (IUD, implant, injection, patch) while on retatrutide, as these bypass the GI absorption pathway entirely
• If using oral contraceptives, discuss backup methods with your physician during dose titration
• This interaction is mechanical (absorption-related), not metabolic — retatrutide does not affect the enzymes that break down hormonal contraceptives

Fertility and the "Ozempic Babies" Phenomenon

Reports of unplanned pregnancies in women taking GLP-1 drugs — dubbed "Ozempic babies" — have received significant media attention. The mechanism is straightforward: weight loss improves metabolic health, reduces insulin resistance, and can restore ovulation in women who were previously anovulatory.

This is not a drug-specific effect. Any substantial weight loss — from medication, surgery, or lifestyle changes — can improve fertility in women with obesity-related anovulation.

Why this matters for retatrutide

Retatrutide produces more weight loss than any other drug in its class (up to 24.2% at 48 weeks in Phase 2, up to 28.7% in TRIUMPH-4). Greater weight loss means a potentially larger fertility restoration effect in women who were previously subfertile due to obesity.

Combined with the potential oral contraceptive interaction described above, this creates a situation where:

1. Fertility may increase (due to weight loss)
2. Oral contraceptive effectiveness may decrease (due to delayed gastric emptying)

Women of reproductive age should discuss contraception planning with their physician before starting retatrutide or any GLP-1 class drug. For detailed coverage of pregnancy safety and washout timing, see our retatrutide and pregnancy guide.

Hair Loss: Higher Weight Loss, Higher Risk

Hair loss during weight loss drug treatment is telogen effluvium — a temporary increase in hair shedding triggered by physiological stress. It is not a direct drug side effect but a consequence of rapid weight loss and caloric deficit.

Across GLP-1 drugs, reported hair loss rates are:

• Semaglutide 2.4mg (Wegovy): 3-5%
• Tirzepatide (Zepbound): 4-6%

Since the severity of telogen effluvium tracks with the magnitude and speed of weight loss, retatrutide's higher weight loss (24-29%) likely places it at the top of this range. The Phase 2 trial did not separately report hair loss rates by sex, but women are generally more likely to notice and report hair shedding.

For detailed coverage of the hair loss mechanism, prevention strategies, and what to expect, see our hair loss and weight loss drugs guide.

Body Composition: The Lean Mass Question

All weight loss involves some lean mass (muscle) loss alongside fat loss. The clinical concern is whether women lose proportionally more lean mass than men — and whether retatrutide's triple-agonist mechanism changes this ratio.

What we know from other drugs

• In semaglutide's STEP 1 DXA sub-study, approximately 39% of total weight lost was lean mass
• In tirzepatide's SURMOUNT-1 DXA sub-study, approximately 25-33% was lean mass
• These sub-studies were not powered to detect sex-based differences in body composition outcomes

Retatrutide body composition data

The Phase 2 DXA sub-study (published in The Lancet Diabetes & Endocrinology, June 2025) measured body composition changes in patients with type 2 diabetes over 36 weeks. This sub-study did not report results stratified by sex.

There are theoretical reasons to expect retatrutide's glucagon receptor activity to favor fat loss over lean mass loss — glucagon promotes lipolysis (fat breakdown) and hepatic fatty acid oxidation. But this hypothesis has not been confirmed in sex-stratified analyses. For more detail, see our muscle loss guide.

Recommendations for women

• Resistance training (2-3 sessions per week) is the most effective intervention for preserving lean mass during weight loss
• Protein intake of 1.2-1.6g/kg/day supports muscle maintenance
• These recommendations are the same regardless of sex, but may be particularly important for older women at risk of sarcopenia

Bone Density: A Concern for Perimenopausal Women

Rapid weight loss reduces bone mineral density — mechanical unloading of the skeleton (less body weight to support) reduces the stimulus for bone maintenance. This is a concern across all weight loss methods, not specific to any drug.

For women, this intersects with menopause-related bone loss:

• Women lose bone density at an accelerated rate during perimenopause and the years immediately following menopause
• Adding significant drug-induced weight loss to this natural decline could increase fracture risk
• No retatrutide-specific bone density data has been published

Women over 45, those in perimenopause, and anyone with existing osteopenia or osteoporosis risk factors should discuss bone density monitoring with their physician before starting any weight loss drug.

Menstrual Cycle Changes

Surveys of women taking GLP-1 drugs report that approximately 27% notice changes to their menstrual cycle. The most commonly reported changes are:

• More predictable periods (45% of those reporting changes)
• More frequent periods (21%)
• Shorter periods (19%)

These changes are likely driven by weight loss improving metabolic and hormonal balance rather than a direct drug effect on reproductive hormones. Most menstrual changes stabilize within 3-6 months.

No retatrutide-specific menstrual cycle data has been published.

PCOS: A Promising but Unproven Application

Polycystic ovary syndrome (PCOS) affects an estimated 6-12% of women of reproductive age and is closely linked to insulin resistance, obesity, and hyperandrogenism. GLP-1 drugs have shown meaningful benefits in PCOS:

• Weight loss improves insulin sensitivity, reduces androgen levels, and can restore ovulatory cycles
• Direct metabolic effects — GLP-1 receptor agonists improve insulin resistance independent of weight loss
• Multi-agonist advantage — a 2024 Nature Communications study found that GLP-1/GIP dual agonists and GLP-1/GIP/glucagon triple agonists produced superior metabolic improvements in PCOS models compared to GLP-1-only drugs

Retatrutide's triple-agonist mechanism — targeting GLP-1, GIP, and glucagon receptors — could theoretically address multiple PCOS pathways simultaneously. GIP receptors are expressed in ovarian tissue, and GIP signaling may play a role in reproductive function beyond its metabolic effects.

However, no retatrutide PCOS trials are currently registered, and the drug has not been studied in a PCOS population. Any potential use in PCOS would require dedicated clinical trials.

What We Do Not Know Yet

• Sex-stratified efficacy data from Phase 3 TRIUMPH trials has not been published. We do not know if women lose more, less, or the same amount of weight as men on retatrutide.
• Oral contraceptive interaction has not been studied for retatrutide specifically. The tirzepatide precedent suggests caution, but the magnitude of any interaction is unknown.
• Long-term reproductive effects of triple agonism are unstudied. GIP receptors in ovarian tissue raise theoretical questions that have not been addressed in clinical trials.
• Bone density effects in women on retatrutide have not been measured.
• PCOS-specific outcomes have not been studied.
• Sex-stratified side effect rates have not been published.

Frequently Asked Questions

Sources

• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. DOI: 10.1016/S0140-6736(23)01053-X
• Eli Lilly. (2025). TRIUMPH-4 Topline Results. Press release
• Truveta Research. Women experience more GLP-1 side effects. Truveta Blog
• Granhall, C., et al. (2015). Semaglutide does not reduce the bioavailability of oral contraceptives. J Clin Pharmacol. PMC4418331
• FDA. Mounjaro (tirzepatide) Prescribing Information. FDA Label
• Kannt, A., et al. (2024). Superior metabolic improvement of PCOS traits after GLP1-based multi-agonist therapy. Nature Communications. DOI: 10.1038/s41467-024-52898-y
• Gaskins, A.J., et al. (2024). GLP-1 RAs in early pregnancy. JAMA Internal Medicine. JAMA
• ClinicalTrials.gov: Retatrutide trials

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

If you have questions about weight loss medications, fertility, contraception, or any other health concern, consult with your healthcare provider. Do not make changes to your medication or contraception based on information about an unapproved drug.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.